Impact News +++ Riot Platforms Soars 17% on $9.1B Anthropic Data Center Deal; AI Infrastructure Peers IREN, Applied... (24/7 Wall St.) +++ RIOT PLATFORMS Aktie +3,06%

PROTARA Aktie

>PROTARA Aktienkurs

3.444 EUR (TradegateBSX)

Ask: 3.512 EUR / 460 Stück

Bid: 3.376 EUR / 480 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PROTARA Aktie über LYNX handeln

Intraday

1 Jahr

>PROTARA Performance

1 Woche: +5,1%

1 Monat: -5,6%

3 Monate: -21,1%

6 Monate: -34,2%

1 Jahr: +32,7%

laufendes Jahr: -21,0%

>PROTARA Aktie

Profil:

Protara Therapeutics Inc. is a biotechnology company focused on developing transformative therapies for rare and speciality diseases. The company's primary function is to innovate treatment solutions for conditions with significant unmet medical need..
>Volltext..

Insiderhandel:

>PROTARA Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>PROTARA Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>PROTARA Chart & Kurs - NASDAQ

>PROTARA News

11.08.26 - 14:09	Protara Therapeutics GAAP EPS of -$0.36 misses by $0.03 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.07.26 - 19:45	What Makes Protara Therapeutics (TARA) a New Buy Stock (Zacks)
	Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

02.07.26 - 00:02	Insiderhandel: CEO and President verkauft Aktien von Protara Therapeutics im Wert von 882160 USD (Insiderkauf)
	Shefferman, Jesse - Vorstand - Tag der Transaktion: 2026-06-29...

20.05.26 - 14:03

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA (GlobeNewswire EN)

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET....

18.05.26 - 14:03	Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 (GlobeNewswire EN)
	Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program...

15.05.26 - 17:42	Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study (Benzinga)
	Protara reports updated Phase 2 data showing durable responses and favorable safety for TARA-002 in bladder cancer patients. Importance Rank: 1 read more...

15.05.26 - 13:03	Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC (GlobeNewswire EN)
	TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients...

13.05.26 - 14:27	Protara Therapeutics GAAP EPS of -$0.31 beats by $0.06 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.04.26 - 22:09

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting (GlobeNewswire EN)

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial evaluating TARA-002 in patients with BCG-Naïve non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming American Urological Association (AUA) 2026 Annual Meeting taking place from May 15, 2026 to May 18, 2026 in Washington, DC....

10.04.26 - 03:01	Insiderhandel: Chief R&D Officer verkauft Aktien von Protara Therapeutics im Wert von 6124 USD (Insiderkauf)
	Zummo, Jacqueline - Vorstand - Tag der Transaktion: 2026-04-08...

05.04.26 - 01:01	Insiderhandel: Chief R&D Officer verkauft Aktien von Protara Therapeutics im Wert von 118865 USD (Insiderkauf)
	Zummo, Jacqueline - Vorstand - Tag der Transaktion: 2026-04-01...

10.03.26 - 20:15	Protara Therapeutics GAAP EPS of -$0.37 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.03.26 - 13:03	Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire EN)
	Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients ...

04.03.26 - 16:15	Protara gains as JP Morgan starts at overweight (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.02.26 - 20:12	Protara falls after mid-stage trial data for lead asset in bladder cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 23:36	Protara Therapeutics: Aktie bricht nach Veröffentlichung von Studiendaten ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

19.02.26 - 14:03	Protara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:...

02.02.26 - 22:09	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
	NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee....

22.01.26 - 14:06

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium (GlobeNewswire EN)

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place from February 26, 2026 to February 28, 2026 in San Francisco....

07.01.26 - 14:03	Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
	NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Werturteile sind nie Wahrheiten, sondern Wünsche, die meist erst wahr gemacht werden sollen. - Ludwig Marcuse

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram